# US 2004/0081964 A1 · Gene and sequence variation associated with sensing carbohydrate compounds and other sweeteners

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081964 A1
- Document ID: US20040081964A1
- Status: Published application
- Kind: A1
- Application number: 10/280,183
- Filed: 2002-10-25
- Published: 2004-04-29
- Earliest claimed: 2002-10-25
- Inventors: Alexander A. Bachmanov; Gary K. Beauchamp; Shannu Li; Xia Li; Danielle R. Reed; Michael Guy Tordoff; David A. Ross; Jeffrey D. Ohman; Aurobindo Chatterjee; Pieter J. De Jong
- Web page: https://patentgrep.com/patent/US20040081964A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to the discovery of a gene and its sequence variation associated with preference for carbohydrates, other sweet compounds, or ethanol. The present invention also relates to the study of metabolic pathways to identify other genes, receptors, and relationships that contribute to differences in sensing of carbohydrates or ethanol. The present invention also relates to germline or somatic sequence variations and its use in the diagnosis and prognosis of predisposition to diabetes, other obesity related disorders, or ethanol consumption. The present invention also provided probes or primers specific for the detection and analysis of such sequence variation. The present invention also relates to method for screening drugs for inhibition or restoration of gene function as antidiabetic, antiobesity, or antialcohol consumption therapies. The present invention relates to other antidiabetic, antiobesity disorder, or antialcohol consumption therapies, such as gene therapy, protein replacement therapy, etc. Finally, the present invention relates to a method for identifying sweeteners or alcohols utilizing the gene and its variations.

## Claims

### Claim 1

An isolated polynucleotide comprising a sequence variation of SEQ ID. NO 1, wherein said variation is associated with sensing carbohydrates, other sweeteners, or ethanol.

### Claim 2

An isolated polynucleotide comprising a sequence variation of SEQ ID. NO 2, wherein said variation is associated with sensing carbohydrates, other sweeteners, or ethanol.

### Claim 3

An isolated polynucleotide comprising a sequence variation of SEQ ID. NO 4, wherein said variation is associated with altered sensation of carbohydrates, other sweeteners, or ethanol.

### Claim 4 (depends on 1)

The polynucleotide of claim 1 wherein said variation is a missense mutation.

### Claim 5 (depends on 4)

The polynucleotide of claim 4 wherein said variation is a nonsense mutation.

### Claim 6

An isolated polypeptide comprising a variant form of SEQ ID. NO: 3, wherein said variant form is associated with altered preference for carbohydrates, other sweeteners, or ethanol.

### Claim 7

An isolated polypeptide comprising a variant form of SEQ ID. NO 5, wherein said variant form is associated with altered preference for carbohydrates, other sweeteners, or ethanol.

### Claim 8 (depends on 1, 2, 3)

An isolated polynucleotide having at least 8 contiguous nucleotides of the polynucleotides of any one of the claims 1-3 wherein said 8 contiguous nucleotides span said variation position.

### Claim 9 (depends on 6, 7)

An isolated polypeptide having at least four contiguous amino acids of the polypeptides of claims 6 or 7 wherein said four contiguous amino acids span said variation position.

### Claim 10 (depends on 8)

An isolated polynucleotide wherein said polynucleotide is substantially identical to the polynucleotide of claim 8.

### Claim 11 (depends on 9)

An isolated polypeptide wherein said polypeptide is substantially identical to the polypeptide of claim 9.

### Claim 12 (depends on 8, 10)

An isolated polynucleotide having a sequence which is complementary to the polynucleotide of claim 8 or 10.

### Claim 13 (depends on 1, 2, 3)

A polynucleotide specific for the SAC1 locus wherein said polynucleotide hybridizes, under stringent conditions, to at least 8 contiguous nucleotides of the polynucleotide of claim 1, 2, 3, or 4.

### Claim 14 (depends on 13)

The polynucleotide according to claim 13 wherein said polynucleotide is selected from the group consisting of SEQ ID. NOS 6-651 and homologous equivalents thereof.

### Claim 15 (depends on 3)

A polynucleotide specific for the SAC1 locus wherein said polynucleotide that hybridizes, under stringent conditions, to at least 8 contiguous nucleotides of the polynucleotide of claim 3.

### Claim 16 (depends on 15)

The polynucleotide of claim 15 wherein said polynucleotide is selected from the group consisting of SEQ ID. NOS 6-651 and homologous equivalents thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 8)

A kit for the detection of the polynucleotide of any one of claims 1-5, 8, and 10 comprising a polynucleotide that hybridizes, under stringent conditions, to at least 12 contiguous nucleotides of the polynucleotide of any one of the claims 1-5, 8, and 10, and instructions relating to detection.

### Claim 18 (depends on 9, 11)

An isolated antibody which is immunoreactive to the polypeptide of claim 9 or 11.

### Claim 19

A method for analyzing a biomolecule in a biological sample, wherein said method comprising:
a) altering SAC1 activity in a biological sample; and
b) measuring the activity.

### Claim 20 (depends on 8, 10)

A method for analyzing a polynucleotide in a biological sample comprising the steps of:
a) contacting a polynucleotide in a biological sample with a probe wherein said probe hybridizes to the polynucleotides of claim 8 or 10 to form a hybridization complex; and
b) detecting the hybridization complex.

### Claim 21 (depends on 8, 10)

A method for analyzing the expression of SAC1 comprising the steps of
a) contacting a biological sample with a probe wherein said probe comprises the polynucleotide of claim 8 or 10; and
b) detecting the expression of SAC1 mRNA transcript in said sample.

### Claim 22 (depends on 19)

The method of claim 19 wherein said step of measuring is an enzymatic assay.

### Claim 23 (depends on 20, 21)

The method of claim 20 or 21 wherein said probe is immobilized on a solid support.

### Claim 24 (depends on 19, 20, 21, 22, 23)

The method according to any one of the claims 19-23 wherein said sample is derived from blood.

### Claim 25 (depends on 19, 20, 21, 22, 23)

The method according to any one of the claims 19-23 wherein said sample is derived from tongue.

### Claim 26 (depends on 19, 20, 21, 22, 23)

The method according to any one of the claims 19-23 wherein said sample is derived from pancreas.

### Claim 27 (depends on 19, 20, 21, 22, 23)

The method according to any one of the claims 19-23 wherein said sample is derived from a human.

### Claim 28

A method for identifying susceptibility to obesity or diabetes which comprises comparing the nucleotide sequence of the suspected SAC1 allele with a wild type nucleotide sequence, wherein said difference between the suspected allele and the wild-type sequence identifies a sequence variation of the SAC1 nucleotide sequence.

### Claim 29 (depends on 3, 8)

An expression vector comprising the polynucleotide of claim 3, 8, or 10.

### Claim 30 (depends on 29)

A host cell comprising the expression vector of claim 29.

### Claim 31 (depends on 30)

A method of producing a polypeptide comprising culturing the cells of claim 30 and recovering the polypeptide from the host cell.

### Claim 32 (depends on 31)

An isolated polypeptide produced according to claim 31.

### Claim 33

A method for conducting a screening assay to identify a molecule which enhances or decreases the SAC1 activity comprising the steps of
a) contacting a biological sample with a molecule wherein said biological sample contains SAC1 activity; and
b) analyzing the SAC1 activity in said sample.

### Claim 34 (depends on 8, 9, 10, 11, 18)

A pharmaceutical composition comprising
a) the polynucleotide of claim 8 or 10, the polypeptide of claim 9 or 11, the antibody of claim 18 or the molecule of claim 18; and
b) a suitable pharmaceutical carrier.

### Claim 35 (depends on 34)

A method for treating or preventing obesity, diabetes, or alcoholism associated with expression of SAC1, wherein said method comprises administering to a subject an effective amount of the pharmaceutical composition of claim 34.

### Claim 36

A transgenic animal that carries an altered SAC1 allele.

### Claim 37 (depends on 36)

The transgenic animal of claim 36 is a knock out mouse.

### Claim 38 (depends on 6, 7)

The polypeptide of claim 6 or 7, wherein said polypeptide is 7-transmembrane G protein coupled receptor (7TM GPCR).
